Intas Pharmaceuticals
Intas Pharmaceuticals, founded in 1976 and headquartered in Ahmedabad, Gujarat, is a large enterprise in the pharmaceuticals industry with a team of 14,812. The company specializes in a wide range of therapeutic areas and invests heavily in R&D, with a strong global presence in over 85 countries.
Company Overview
Intas Pharmaceuticals operates in the Pharmaceuticals industry and was founded in 1976. With a team size of 14,812, it is classified as a very large enterprise. The company is headquartered in Ahmedabad, Gujarat, India, and describes its mission as 'Expressions for a Healthy Life.' Intas has established a significant presence in the global market, with operations in over 85 countries and approximately 70% of its revenues derived from international markets, particularly in the EU and US.
Products and Specialties
Intas Pharmaceuticals specializes in a diverse range of therapeutic areas, including biosimilars development, recombinant proteins manufacturing, and chronic therapies. The company's product portfolio includes formulations for oncology, central nervous system disorders, cardio-diabetes, women's health, gastroenterology, urology, and autoimmune diseases. Intas also focuses on generic medicine and new drug delivery systems (NDDS), with a strategic pipeline of over 300 high-value products.
Research and Development
Research and development is central to Intas Pharmaceuticals' operations, with the company investing approximately 6-7% of its revenues in this area. The company boasts over 100,000 square feet dedicated to R&D and employs more than 550 scientists and researchers. Intas has a progressive product basket that includes generics, oncology, and parenteral products. The company has achieved over 10,000 product registrations worldwide and operates 16 advanced facilities for R&D and distribution.
Manufacturing and Certifications
Intas Pharmaceuticals operates 17 advanced manufacturing facilities, with 10 located in India and others in the UK, Mexico, and Greece. Its manufacturing facilities are approved by major global regulatory agencies, including USFDA, MHRA, EMA, TGA, MCC, and ANVISA. The company’s Plasma Fractionation Unit is recognized for its WHO-GMP-certified manufacturing of plasma-derived therapeutics. The Biopharma division is EU-GMP certified, focusing on affordable biosimilars in niche segments.
Global Presence and Growth
Intas Pharmaceuticals has a strong global presence, with operations in more than 85 countries. The company has experienced significant growth, with an approximate CAGR of 22%. It has expanded its market reach through strategic acquisitions, including the generics business of Actavis in the UK and Ireland, and the hospital business in Spain and Portugal. Intas is also known for launching key products such as rituximab and Azacitidine in India, contributing to lowering cancer treatment costs.